130 / 160
130
(9);1:51-54.
32. Chatwin M, Bush A, Simonds AK. Outcome of goal-directed
non-invasive ventilation and in spinal muscular atrophy type
I. Arch Dis Child. 2011 May; 96(5):426-32.
33. Bach JR, Gonçalves MR, Hon A, et al. Changing Trends in the
Management of End-Stage Neuromuscular Respiratory Muscle
Failure. Recommendations of an International Consensus. Am J
Phys Med Rehabil 2012;91:1-11.
34. Bach JR, Nirajan V, Weaver B. Spinal muscular atrophy type I:
a non invasive respiratory approach. Chest 2000;117:1100-
1105.
35. Bach JR, Vega J, Majors J, Frieman A. Spinal muscular atrophy
type 1 quality of life. Am J Phys Med Rehabil 2003;82(2):137–
42.
36. Ryan MM, Kilham H, Jacobe S, Tobin B, Isaacs D. Spinal
muscular atrophy type 1: is long-term mechanical ventilation
ethical? J. Paediatr. Child Health 2007; 43: 237–42.
37. Lillo s. El proceso de comunicar y acompañar a los padres y
al paciente frente al diagnóstico de discapacidad. REV. MED.
CLIN. CONDES 2014; 25(2) 372-379.
38. Simonds A. Ethical aspects of home long term ventilation in
children with neuromuscular disease. Paediatr Respir Rev.
2005 Septiembre; 6(3).
39. Bach J, Saltstein K, Sinquee D, Weaver B, Komaroff E. Long-
Term Survival in Werdnig– Hoffmann Disease. Am. J. Phys. Med.
Rehabil. 2007 Mayo; 86(5).
40. Schroth MK. Special Considerations in the Respiratory
Management of Spinal Muscular Atrophy. Pediatrics
2009;123:S245-S249.
41. MINISTERIO DE SALUD. Guía Clínica Cuidados respiratorios
en personas con Atrofia Muscular Espinal, Santiago: Minsal,
2014.
42. Gregoretti C, Ottonello G, Chiarini M, Mastella C, Ravà L,
Bignamini E, et al. Survival of Patients With Spinal Muscular
Atrophy Type 1. Pediatrics. 2013 Abril; 131.
43.
www.avexis.com44. Sivanesan s, Howell MD, Didonato CJ, Singh RN. Antisense
oligonucleotide mediated therapy of spinal muscular atrophy.
Trails Neurosci 2013;4:1-12.
[REV. MED. CLIN. CONDES - 2017; 28(1) 119-130]